Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
BerGenBio, following lead drug's failure, merges with Oncoinvent
BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.
James Waldron
Jul 1, 2025 7:00am
Ernexa's stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025 2:30pm
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Mar 31, 2025 10:25am
Acrivon stops testing Lilly castoff for ovarian, bladder cancer
Mar 26, 2025 7:05am
Sutro discards CEO, 50% of staff and lead ADC to save cash
Mar 14, 2025 7:05am
Zentalis lays off 40% to fund registrational trial of WEE1 drug
Jan 29, 2025 4:42am
